Slide 1: Aroa Biosurgery Quarterly Report
For personal use only Aroa Biosurgery (ARX) | Quarterly Report UNLOCKING REGENERATIVE HEALING FOR EVERYBODY
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only This presentation (Presentation) is dated 22 October 2024 and has been prepared by Aroa solely on their own judgement, review and analysis when making an investment decision Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AR
Slide 3: Q2 FY25 Financial Highlights
Q2 FY25 Financial Highlights For personal use only Net cash outflow from operations was NZ$1.2 million, a $2.4 million improvement vs previous quarter. The Company expects to be operating cash flow 01 positive in H2 FY25. Net cash outflow from investing activities was NZ$0.6 million reflecting routi
Slide 4: Q2 FY25 Operational Highlights
Q2 FY25 Operational Highlights For personal use only Momentum behind AROA’s US commercial operations 01 continues to build. 5% (Q-on-Q) growth in Myriad active accounts to 265. Regulatory approval for Endoform and Myriad Matrix 02 in Argentina, and Endoform in Egypt. Four peer reviewed studies publi
Slide 5: Myriad Sales
SALES Myriad Sales For personal use only 01 Top priority >70% YoY 02 Momentum Growth 16 03 Large volumetric defects 14 12 04 Compelling clinical data 10 05 Disruptive Value US$M 8 6 MYRIAD US$ 14M 4 2 TOTAL ADDRESSABLE 0 MARKET FY20 FY21 FY22 FY23 FY24 US$ 730M
Slide 6: TELA Bio Sales
SALES TELA Bio Sales For personal use only 01 Key partnership 40% YoY Hernia & Growth 02 breast reconstruction portfolio 70 60 03 Momentum 50 04 Compelling clinical data 40 05 Disruptive value US$m 30 OVITEX 20 US$ 63M 10 TOTAL ADDRESSABLE 0 MARKET FY20 FY21 FY22 FY23 FY24 US$ 1.9B
Slide 7: Aroa's Competitive Advantage
For personal use only AROA’S COMPETITIVE ADVANTAGE
Slide 8: Aroa's Competitive Advantage: Value
AROA'S COMPETITIVE ADVANTAGE Value For personal use only 01 Improved clinical outcomes 02 Low complication rates 03 Fewer applications 04 Shorter length of stay 05 Reduced product cost
Slide 9: Product portfolio/development
AROA'S COMPETITIVE ADVANTAGE Product portfolio/development For personal use only 01 AROA ECM scope 02 Unique technical capabilities 03 Complementary Enivo platform
Slide 10: Low cost of goods
AROA'S COMPETITIVE ADVANTAGE Low cost of goods For personal use only 01 High margin manufacturing 02 Continuous improvement 03 Scalable modular process
Slide 11: Aroa Growth: Financial outlook
AROA GROWTH Financial outlook 1 FY24 FY25 GUIDANCE For personal use only Product Product Revenue NZ$ Revenue NZ$ 01 Myriad & OviTex drive growth 69 MILLION 80-87 MILLION (YoY growth ~25% CAGR 19 – 24%) 02 Gross margin improves Product Product Gross Margin Gross Margin 03 Sales operating leverage 85%
Slide 12: Questions & Answers
For personal use only AROA BIOSURGERY Questions & Answers
Slide 13: Thank you for attending
Thank you For personal use only for attending JAMES AGNEW investor@aroa.com VISIT www.aroa.com www.linkedin.com/company /aroa-biosurgery-limited/ 64 Richard Pearse Drive, Auckland 2022, New Zealand PO Box 107111, Auckland Airport, Auckland 2150, New Zealand